NYSE:AMAM

Ambrx Biopharma - AMAM Stock Forecast, Price & News

$1.85

-0.03 (-1.60%)

(As of 02/2/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.77
▼
$1.92
50-Day Range: $0.41
▼
$4.54
52-Week Range: $0.38
▼
$5.12

Volume: 278,240 shs
Average Volume: 720,049 shs
Market Capitalization: $71.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Institutional Ownership

Ambrx Biopharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 116.2% Upside
$4.00 Price Target
Short Interest: Healthy
1.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.24) to ($0.04) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

598th out of 1,030 stocks

Biological Products, Except Diagnostic Industry

92nd out of 169 stocks

3.3

Analyst's Opinion

Consensus Rating
Ambrx Biopharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Ambrx Biopharma has a forecasted upside of 116.2% from its current price of $1.85.
Amount of Analyst Coverage
Ambrx Biopharma has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.94% of the float of Ambrx Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Ambrx Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ambrx Biopharma has recently decreased by 26.26%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Ambrx Biopharma does not currently pay a dividend.
Dividend Growth
Ambrx Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMAM.

0.0

News and Social Media Coverage

Search Interest
Only 21 people have searched for AMAM on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Ambrx Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -94% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ambrx Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Ambrx Biopharma is held by insiders.
Percentage Held by Institutions
43.14% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Ambrx Biopharma are expected to grow in the coming year, from ($0.24) to ($0.04) per share.
Price to Book Value per Share Ratio
Ambrx Biopharma has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ambrx Biopharma (NYSE:AMAM) Stock

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

AMAM Stock News Headlines

January 24, 2023 | americanbankingnews.com

Ambrx Biopharma (NYSE:AMAM) versus Fennec Pharmaceuticals (NASDAQ:FENC) Head-To-Head Survey

January 18, 2023 | seekingalpha.com

Ambrx Biopharma: Some Promise, Much Uncertainty

February 2, 2023 | PressReach (Ad)

Top Innovation Stock

Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.

January 16, 2023 | finance.yahoo.com

The past year for Ambrx Biopharma (NYSE:AMAM) investors has not been profitable

December 19, 2022 | msn.com

Ambrx Biopharma receives NYSE notice for non-compliance

December 16, 2022 | finance.yahoo.com

Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price

December 11, 2022 | markets.businessinsider.com

Cowen & Co. Keeps Their Buy Rating on Ambrx Biopharma (AMAM)

December 11, 2022 | finance.yahoo.com

Meet the Biotech Stock That Jumped Over 1000% in One Day

February 2, 2023 | Investor Place Media (Ad)

Cash Holders STILL Aren't Taking Steps to Prepare

Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.

December 9, 2022 | benzinga.com

Thinking about buying stock in Ambrx Biopharma, Plug Power, Hello Group, Credit Suisse, or Carvana?

December 9, 2022 | seekingalpha.com

Ambrx stock surges 160% as drug shows promise in phase 2 breast cancer trial

December 9, 2022 | finance.yahoo.com

Ambrx Shares Surge After Encouraging Early Safety, Efficacy Data From Breast Cancer Candidate

December 9, 2022 | finance.yahoo.com

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

December 6, 2022 | finance.yahoo.com

Can Ambrx Biopharma (NYSE:AMAM) Afford To Invest In Growth?

November 29, 2022 | finance.yahoo.com

Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium

November 14, 2022 | seekingalpha.com

Week In Review: Insilico Signs Six-Drug AI Discovery Deal With Sanofi Worth Up To $1.2 Billion

November 9, 2022 | finance.yahoo.com

Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70

November 1, 2022 | finance.yahoo.com

Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer

October 19, 2022 | finance.yahoo.com

Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason

October 18, 2022 | finance.yahoo.com

Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

October 11, 2022 | finance.yahoo.com

Ambrx Biopharma to Host Corporate Update Conference Call

August 29, 2022 | finance.yahoo.com

Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update

August 19, 2022 | wsj.com

Ambrx Biopharma Inc. ADR

August 16, 2022 | marketwatch.com

Ambrx Biopharma Names Kate Hermans Interim Chief Executive Officer

August 16, 2022 | finance.yahoo.com

Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian

July 5, 2022 | finance.yahoo.com

Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors

June 28, 2022 | finance.yahoo.com

Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

AMAM Company Calendar

Today: 2/02/2023
Next Earnings (Estimated): 4/25/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:AMAM
CUSIP: N/A
CIK: 1836056
Web: ambrx.com
Phone: 858-875-2400
Fax: N/A
Employees: 70
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +116.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.70
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $7.45 million
Price / Sales: 9.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.92 per share
Price / Book: 0.38

Miscellaneous

Outstanding Shares: 38,620,000
Free Float: 36,648,000
Market Cap: $71.45 million
Optionable: Not Optionable
Beta: -2.17

Key Executives

Ms. Sonja Nelson CPA (Age 49)
Chief Financial & Operating Officer

Mr. Daniel J. O'Connor J.D. (Age 57)
CEO, Pres & Director

Dr. Ying J. Buechler Ph.D.
Chief Technology Officer

Dr. Shawn Shao-Hui Zhang Ph.D.
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

AMAM Stock - Frequently Asked Questions

Should I buy or sell Ambrx Biopharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMAM shares.
View AMAM analyst ratings or view top-rated stocks.
What is Ambrx Biopharma's stock price forecast for 2023?: 2 brokers have issued 1-year price targets for Ambrx Biopharma's stock. Their AMAM share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 112.8% from the stock's current price.
View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts.
How have AMAM shares performed in 2023?: Ambrx Biopharma's stock was trading at $2.27 on January 1st, 2023. Since then, AMAM shares have decreased by 17.2% and is now trading at $1.88.
View the best growth stocks for 2023 here.
Are investors shorting Ambrx Biopharma?: Ambrx Biopharma saw a decrease in short interest in the month of December. As of December 30th, there was short interest totaling 965,700 shares, a decrease of 48.6% from the December 15th total of 1,880,000 shares. Based on an average trading volume of 3,470,000 shares, the short-interest ratio is presently 0.3 days. Currently, 2.6% of the shares of the stock are sold short.
View Ambrx Biopharma's Short Interest.
When is Ambrx Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023.
View our AMAM earnings forecast.

When did Ambrx Biopharma IPO?: (AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO.
What is Ambrx Biopharma's stock symbol?: Ambrx Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMAM."
Who are Ambrx Biopharma's major shareholders?: Ambrx Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Ambrx Biopharma?: Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ambrx Biopharma's stock price today?: One share of AMAM stock can currently be purchased for approximately $1.88.
How much money does Ambrx Biopharma make?: Ambrx Biopharma (NYSE:AMAM) has a market capitalization of $72.61 million and generates $7.45 million in revenue each year.
How can I contact Ambrx Biopharma?: The official website for the company is ambrx.com. The company can be reached via phone at 858-875-2400.

This page (NYSE:AMAM) was last updated on 2/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ambrx Biopharma - AMAM Stock Forecast, Price & News

Ambrx Biopharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ambrx Biopharma (NYSE:AMAM) Stock

AMAM Stock News Headlines

AMAM Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AMAM Stock - Frequently Asked Questions

Overall MarketRank^™